Inventiva S.A. (NASDAQ:IVA) Short Interest Up 562.1% in October

Inventiva S.A. (NASDAQ:IVA) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 853,400 shares, a growth of 562.1% from the September 30th total of 128,900 shares. Based on an average daily volume of 201,000 shares, the short-interest ratio is presently 4.2 days.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors own 19.06% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on IVA. HC Wainwright lowered their target price on Inventiva from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, October 15th. Stifel Nicolaus decreased their price objective on Inventiva from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, September 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inventiva currently has an average rating of “Buy” and a consensus target price of $16.25.

Inventiva Trading Up 7.3 %

IVA traded up $0.18 during trading on Friday, hitting $2.66. The company’s stock had a trading volume of 52,543 shares, compared to its average volume of 635,131. Inventiva has a twelve month low of $1.53 and a twelve month high of $4.75. The firm’s 50 day moving average price is $2.22 and its 200-day moving average price is $2.74.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.